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Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is one of the
most common inherited disorders in humans and the majority of patients carry a variant
in either PKD1 or PKD2. Genetic testing is increasingly required for diagnosis, prognosis,
and treatment decision, but it is challenging due to segmental duplications of PKD1,
genetic and allelic heterogeneity, and the presence of many variants hypomorphic or of
uncertain significance. We propose an NGS-based testing strategy for molecular analysis
of ADPKD and its phenocopies, validated in a diagnostic setting.
Materials and Methods: Our protocol is based on high-throughput simultaneous
sequencing of PKD1 and PKD2 after long range PCR of coding regions, followed by
a masked reference genome alignment, and MLPA analysis. A further screening of
additional 14 cystogenes was performed in negative cases. We applied this strategy
to analyze 212 patients with a clinical suspicion of ADPKD.
Results and Discussion: We detected causative variants (interpreted as
pathogenic/likely pathogenic) in 61.3% of our index patients, and variants of uncertain
clinical significance in 12.5%. The majority (88%) of genetic variants was identified
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in PKD1, 12% in PKD2. Among 158 distinct variants, 80 (50.6%) were previously
unreported, confirming broad allelic heterogeneity. Eleven patients showed more than
one variant. Segregation analysis indicated biallelic disease in five patients, digenic in
one, de novo variant with unknown phase in two. Furthermore, our NGS protocol allowed
the identification of two patients with somatic mosaicism, which was undetectable with
Sanger sequencing.
Among patients without PKD1/PKD2 variants, we identified three with possible
alternative diagnosis: a patient with biallelic mutations in PKHD1, confirming the overlap
between recessive and dominant PKD, and two patients with variants in ALG8 and
PRKCSH, respectively.
Genotype-phenotype correlations showed that patients with PKD1 variants predicted
to truncate (T) the protein experienced end-stage renal disease 9 years earlier than
patients with PKD1 non-truncating (NT) mutations and >13 years earlier than patients
with PKD2mutations. ADPKD-PKD1T cases showed a disease onset significantly earlier
than ADPKD-PKD1NT and ADPK-PKD2, as well as a significant earlier diagnosis. These
data emphasize the need to combine clinical information with genetic data to achieve
useful prognostic predictions.
Keywords: polycystic kidney disease, ADPKD, PKD1, PKD2, NGS, cystogenes
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is one
of the most common inherited disorders in humans, with an
estimated prevalence between 1/400 and 1/1000 in the general
population (Torres et al., 2007). It is characterized by the
development and progressive enlargement of renal cysts, which
often leads to end-stage renal disease (ESRD) (Gabow, 1993;
Grantham et al., 2011). ADPKD is mainly caused by mutation
in either PKD1 (74–85% of patients) or PKD2 (15–26%) (Rossetti
et al., 2007; Barua et al., 2009; Carrera et al., 2016), with PKD2
variants being relatively more frequent in Japan (Kurashige et al.,
2015). Furthermore, mutations in GANAB and DNAJB11 were
recently shown to cause polycystic kidney in a small percentage
(0.3%) of affected subjects (Porath et al., 2016; Cornec-Le Gall
et al., 2018). Patients with PKD1 mutations usually develop a
more severe disease than patients with PKD2, with more cysts
at an earlier age (Hateboer et al., 1999; Torres et al., 2007), and
truncating mutations in PKD1 lead to earlier ESRD than non-
truncating ones (Cornec-Le Gall et al., 2013). Intra and inter
familial disease severity is also reported, suggesting a role for
environmental factors and the genetic background. Additional
genetic defects are sometime identified in rare cases with early
onset disease, i.e., mutations in the second PKD allele, or in other
genes such as PKHD1 or HNF1B (Rossetti et al., 2009; Bergmann
et al., 2011; Audrézet et al., 2016). Somatic mosaicism and
hypomorphic alleles contribute to further increase the genetic
complexity of this condition (Connor et al., 2008; Rossetti et al.,
2009; Vujic et al., 2010).
Although the diagnosis of ADPKD is usually based on imaging
studies, a genetic test is currently indicated in patients without a
positive family history, with atypical clinical or imaging features,
and in helping the identification of a familial donor for renal
transplantation. In addition, a genetic diagnosis may guide
clinical management and treatments, and it may improve the
accuracy of genetic counseling. Genetic analysis is not uniformly
required by nephrologists in standard clinical practice. However,
information on specific mutations may help to predict disease
progression using the PROPKD score, which can guide the
selection of patients who will best benefit from the use of
Tolvaptan, a vasopressin 2 receptor antagonist (Cornec-Le Gall
et al., 2016, 2019).
The cost of analysis and technical challenges prevented
a widespread application of PKD1 sequencing. This gene
has six pseudogenes with high sequence homology, in a
duplicated region adjacent to the original PKD1 locus. In
addition, its large size and high GC content, the extensive
allelic heterogeneity of PKD1 (and PKD2 as well) and genetic
heterogeneity further complicate the molecular screening. Next-
generation sequencing (NGS) technologies revolutionized the
approach to molecular diagnostics and have recently been
applied to ADPKD as well, with different strategies. Targeted
re-sequencing was performed by generating long-range (LR)
locus-specific PCR amplicons and multiplexing them from
individuals samples as bar-coded libraries for NGS (Rossetti
et al., 2012; Tan et al., 2014; Kinoshita et al., 2016). An
alternative approach was a sequence capture-based NGS,
with improved algorithms in order to overcome unspecific
capture of pseudogenes (Trujillano et al., 2014; Eisenberger
et al., 2015). A long-read single-molecule sequencing was
recently suggested as a strategy to overcome PKD1 complexities
(Borràs et al., 2017). Finally, a comprehensive approach
with 140 candidate gene-panel for cystic and glomerular
nephropathies has been proposed (Bullich et al., 2018). All
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these methods have strengths and pitfalls, and should be
further validated.
Here, we propose an NGS-based testing strategy for molecular
diagnosis of ADPKD and its phenocopies, validated in a
diagnostic setting. Our workflow included LR-PCR targeted
re-sequencing for both PKD1 and PKD2, combined with a
specific alignment pipeline for PKD1. Large rearrangements
were assessed by multiplex-ligation probe amplification (MLPA).
Additional cystogenes, namelyGANAB,DNAJB11, LRP5, PMM2,
PRKCSH, SEC63, SEC61B, ALG8, PKHD1, DZIP1L, HNF1B,
UMOD, INF2, and REN (Porath et al., 2016; Cornec-Le Gall
et al., 2017; Bullich et al., 2018), were also tested by NGS targeted
re-sequencing in PKD1/2 negative patients, after clinical revision.
MATERIALS AND METHODS
Patient Recruitment
Most patients were recruited from the Units of Nephrology and
Medical Genetics of Bologna University Hospital, a few from
partner centers. Written informed consents for genetic analysis
and publication of results were obtained from the patients or their
parents/guardians in compliance with national ethics regulation.
The families received pre- and post-test genetic counseling.
The 212 patients enrolled in the study belonged to the
following three groups: (1) a validation cohort included
21 ADPKD patients that had previously undergone genetic
diagnosis by Sanger sequencing of PKD1 and PKD2; (2) a group
of 36 patients with a clinical diagnosis of severe ADPKD, who
had already received a kidney transplantation, was included as a
confirmation cohort; (3) a third group was a discovery cohort,
including 155 unrelated patients who had been consecutively
referred for ADPKD genetic testing from 2014 to 2018. In
addition, 143 family members were tested for the possible
pathogenic variants detected in the probands.
Main clinical features of patients submitted to the study
are summarized in Table 1, while the most significant clinical
histories are extrapolated and described in the Results section.
The diagnosis of ADPKD relies primarily on imaging,
although some cases are diagnosed by genetic testing. Typical
ultrasonography imaging reveals large kidneys with multiple
bilateral cysts. Imaging is also the first choice for pre-
symptomatic diagnosis of patients with a positive family history.
Specifically, Pei’s criteria suggest that the presence of a total of
three or more kidney cysts for at-risk individuals aged 15–39
years and 2 or more cysts in each kidney for at-risk individuals
aged 40–59 years are sufficient for a clinical diagnosis. The
absence of kidney cysts on ultrasound excludes ADPKD in
patients older than 40 years. If ultrasonography images are
equivocal, magnetic resonance imaging (MRI) or computed
tomography (CT) may clarify the diagnosis (Pei et al., 2009).
Library Preparation
Genomic DNA was isolated from EDTA peripheral blood
using the semi-automatic Maxwell 16 instrument (Promega
Corporation, Madison, WI USA).
The PKD1 (MIM#601313 HGNC:9008, RefSeq NM
_001009944.2) entire coding region, including exon-intron
TABLE 1 | Clinical characteristics of study patients.
N. %
Index patients 212
Italians 190 89.6
Women 113 53.3
Positive family history (n = 193) 148 76.7
Presence of liver cysts (n = 159) 128 80.5
Vascular abnormalities (n = 121) 24 19.8
Urological events before 35 yr (n = 128) 34 26.6
Antihypertensive treatment before 35 yr (n = 133) 54 40.6
ESRD (n = 165) 42 25.5
Transplantation (n = 177) 45 25.4
ADPKDVEO (n = 163) 7 4.3
ADPKDEO (n = 163) 23 14.1
Median value
Age at test, yr (n = 212) 50
Age at onset, yr (n = 163) 25
Age at diagnosis, yr (n = 156) 41
Serum creatinine at presentation, mg/dl (n = 155) 1.15
GFR at presentation, ml/min (n = 131) 66
The number of cases for which the data was available is shown in brackets. ESRD, End-
Stage Renal Disease; GFR, Glomerular Filtration Rate; VEO, Very Early Onset (diagnosed
in utero or before 18 months); EO, Early Onset (diagnosed before 15 years).
boundaries (at least 50 bp) and most of the 5′ and 3′ untranslated
regions were amplified in eight long-range (LR) PCR using
specific primers anchored on the rare mismatch sequencing
between PKD1 and pseudogenes. We combined previously
described primers (Audrézet et al., 2012; Tan et al., 2014;
Kinoshita et al., 2016) with primers designed by us and
we optimized the PCR protocols. A LR-PCR method was
validated also for PKD2 (MIM#173910 HGNC:9009, RefSeq
NM_000297.3), using previously described primers (Tan
et al., 2014). Primers and PCR conditions are reported in
Supplementary Table 1.
For each patient, all 13 LR-PCR products (37.8 kb for PKD1
and 35.9 kb for PKD2) were pooled together in equimolarmanner
(50 pM each), the pools were then subjected to enzymatic
digestion using Ion Xpress Plus Fragment Library Kit, in order
to obtain about 200 bp fragments. Fragmented LR-PCRs were
used to construct barcoded libraries using Ion Xpress Barcode
Adapters following the manufacturer’s protocol. A single barcode
was used for simultaneous analysis of both genes for each patient.
Size selection of fragments was performed by E-Gel Size Select II
2% agarose gel (Thermo Fisher Scientific Inc.).
Patients without PKD1/PKD2 genetic defects were revised
by clinicians and, if appropriate, were tested for mutations in
additional genes. To this aim, we developed a multiplexed
PCR NGS for a panel including the novel described
ADPKD genes (GANAB, MIM#600666 HGNC:4138 RefSeq
NM_198335.3; DNAJB11, MIM#611341 HGNC:14889 RefSeq
NM_016306.5), the autosomal dominant polycystic liver
disease (ADPLD) genes (LRP5, MIM#603506 HGNC:6697
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RefSeq NM_002335.3; PMM2 MIM#601785 HGNC:9115
RefSeq NM_000303.2; PRKCSH, MIM#177060 HGNC:9411
RefSeq NM_002743.3; SEC63, MIM#608648 HGNC:21082
RefSeq NM_007214.4; SEC61B, MIM#609214 HGNC:16993
RefSeq NM_006808.2; ALG8, MIM#608103 HGNC:23161
RefSeq NM_024079.4), the two genes for ARPKD (PKHD1,
MIM#606702 HGNC:9016 RefSeq NM_138694.3 and DZIP1L,
MIM#617570 HGNC:26551 RefSeq NM_173543.2), and
additional cystogenes (HNF1B, MIM#189907 HGNC:11630
RefSeq NM_000458.3; UMOD, MIM#191845 HGNC:12559
RefSeq NM_001008389.2; INF2, MIM#610982 HGNC:23791
RefSeq NM_022489.3; REN, MIM#179820 HGNC:9958 RefSeq
NM_000537.3). Amplicon-based libraries were generated from
10 ng of DNA per sample using Ion AmpliSeq Library Kit Plus
according to the manufacturer’s instructions (Thermo Fisher
Scientific Inc.).
Template Generation and Sequencing
The barcoded libraries were quantified using Ion Library TaqMan
Quantitation Kit and pooled in equimolar manner (9 pM), then
the emulsion PCR was performed using the Ion OneTouch 2
System (Thermo Fisher Scientific Inc.). The enriched emulsion-
PCR was then prepared for sequencing protocol using Ion
PGM Hi-Q Sequencing Kit, loaded onto an Ion 318v2 chip
and sequenced with the Ion Personal Genome Machine (PGM).
For PKD1 and PKD2 genes, 12 patients were simultaneously
analyzed in each chip. Recently, we introduced the HID Ion
Chef instrument for emulsion PCR and enrichment, united with
Ion Gene Studio System S5 (Thermo Fisher Scientific Inc). We
simultaneously analyzed 16 patients on an Ion 520 chip. For the
other genes, the number of patients per chip has been calculated
to obtain an average cover of at least 500x.
Data Analysis
The raw sequencing data were transferred to the Torrent
Server where the Torrent SuiteTM performed the alignment to
a reference genome in order to generate Fastq files, Binary
Alignment Map (BAM) in conjunction with Binary Alignment
Index (BAI) and Variant Call Format (VCF) files. PKD1 reads
were aligned against a modified reference genome based on
chromosome 16 of Human Genome 38 (Grch38), where all the
nucleotides outside the PKD1 locus were masked and replaced
with “Ns.” All the VCF files were uploaded into Ion Reporter
software (Thermo Fisher Scientific Inc.) selecting the Annotation
Variant workflow in order to associate to each variant the
nucleotide change in mRNA transcript, the aminoacidic change,
the exons or IVSs and the function.
The BAM/BAI files, generated following the alignment, were
visualized using Integrative Genome Viewer (IGV) software1.
IGV was used to assess the depth of coverage of the sequencing
reads, zygosity, quality of the sequencing reads and the
mapping quality.
1Integrative Genome Viewer (IGV). http://www.broadinstitute.org/igv
Filtering and Classification of the Gene
Variants
Variant filtering based on population frequency was performed
using population databases ExAC, gnomAD (Lek et al., 2016),
1000Genomes (1000 Genomes Project Consortium et al., 2015)
and dbSNP database to include only rare alleles (minor allele
frequency ≤1%).
The variants were then annotated according to the
guidelines published by the Human Genome Variation
Society2 (Den Dunnen and Antonarakis, 2000) and classified
in five categories, according to the American College
of Medical Genetics and Genomics (ACMG) standards
(Richards et al., 2015). Segregation analysis was performed
in additional affected family members whenever possible.
The protein truncating (PT) mutations (frameshift, non-
sense, canonical splice-site and large-gene rearrangements)
were considered pathogenic (P). The non-truncating (NT)
variants (in-frame insertion/deletion, non-synonymous and
synonymous variants) were attributed to one of the other
four categories, by using the VarSomeClinical platform3.
We also checked variants in mutation database PKDB4,
in Leiden Open Variations PKD Database5, in Human
Gene Mutation Database (Stenson et al., 2017), in ClinVar
archive6 and by segregation analysis, and we re-classified them
when appropriate.
In addition to the five categories defined by ACMG standards,
we classified some PKD variants as hypomorphic (H), according
to the literature or databases. We also re-classified H some non-
truncating PKD1 alleles showing incomplete penetrance through
family study.
Missense variants predicted to be neutral, rare synonymous
and intronic variants predicted as not affecting function, deep
intronic and frequent synonymous variants in non-conserved
sequence domains were classified likely benign (LB) or benign (B)
and are not reported.
We performed an additional bioinformatics analysis for
missense variants of uncertain significance (VUS) and for H
variants by using PyMOL, an open source molecular graphics
system 2.0 Schrodinger, LLC7. Five variants in PKD1 and two
variants in PKD2, lying in the crystalized portion of the proteins
(PDB number: 6A70), were submitted to the tool.
Sanger Sequencing and MLPA
All the variants considered as pathogenic, likely pathogenic
and VUS were confirmed by Sanger sequencing on 3730
DNA Analyzer (Applied Biosystem, Foster City, CA, USA).
Coding and splicing regions with low coverage (<20x)
have also been sequenced by the Sanger method. For the
exons 1-33 of PKD1, we performed a nested PCR of the
2Human Genome Variation Society. http://www.hgvs.org/mutnomen
3VarSomeClinical platform. https://varsome.com
4Mutation database PKDB. https://pkdb.mayo.edu
5Leiden Open Variations PKD database. https://databases.lovd.nl/shared/genes/
PKD1; https://databases.lovd.nl/shared/genes/PKD2
6ClinVar. http://www.ncbi.nlm.nih.gov/clinvar
7PyMOL. www.pymol.org/2
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TABLE 2 | Patient groups and positives for pathogenic/likely pathogenic variants in PKD1/PKD2.
All (n = 212) Validation cohort (n = 21) Confirmation cohort (n = 36) Discovery cohort (n = 155)
n % n % n % n %
PKD1/PKD2 Positive 138 65.1 21 100.0 31 86.1 86 55.5
ADPKD-PKD1 118 85.5 18 85.7 28 90.3 72 83.7
ADPKD-PKD1T 92 78.0 12 66.7 25 89.3 55 76.4
ADPKD-PKD1NT 26 22.0 6 33.3 3 10.7 17 23.6
ADPKD-PKD2 20 14.5 3 14.3 3 9.7 14 16.3
PKD1/PKD2 Negative 74 34.9 0 0.0 5 13.9 69 44.5
PKD1/2 VUS 24 11.3 0 0.0 3 8.3 21 13.5
ADPKD-PKD1VUS 21 87.5 0 0.0 3 100.0 18 85.7
ADPKD-PKD2VUS 3 12.5 0 0.0 0 0.0 3 14.3
One proband, homozygous for a hypomorphic PKD1 variant, is also included among the positives. Patients showing variants of uncertain significance (VUS) are also reported and
included among the negatives. T, protein truncating; NT, protein non-truncating.
interested region from LR amplicons before proceeding to
Sanger sequencing.
Samples without variants classified as P or LP in PKD1/PKD2,
including those presenting a VUS, were analyzed by
MLPA for detection of large gene rearrangements, using
commercially kits SALSA MLPA P351 PKD1 and SALSA MLPA
P352 PKD1-PKD2 probemix (MRC-Holland, Amsterdam,
NL). Fragment analysis of the PCR product was carried
out on 3730 DNA Analyzer and the electropherograms
were analyzed by Coffalyzer software (MRC Holland,
Amsterdam, NL).
Statistical Analyses
Continuous variables were reported as mean if normally
distributed and median if not, and discrete variables were
reported as percentages. The statistical significance has been
tested by Pearson’s Goodness of Fit Chi-square for categorical
variables. Fisher Exact test has been applied in the case of a
value less than five in one of the cells. One-way analysis of
variance was performed for continuous traits measurement of
central tendency. We performed the analysis using the Statistix
8 software (Analytical Software, FL, USA).
RESULTS
Identification of PKD1 or PKD2 Genetic
Defects in Probands
The NGS performed on LR-PCR libraries for PKD1 and
PKD2 showed an excellent read depth, providing an average
base coverage of 1,156x without gaps. On average, 92% of
target sequences were covered >20x, but the regions with
lower coverage were mainly in deep introns. The exon 1
of PKD1, usually difficult to sequence due to its high GC
content, resulted entirely sequenced, with an average coverage
at 100x.
We adopted the recently suggested nosology, describing the
disease and the genetic etiology of ADPKD, classifying the
patients as ADPKD-PKD1T/NT or ADPKD-PKD2, as shown in
Table 2 (Eckardt et al., 2015; Cornec-Le Gall et al., 2017). Patients
harboring more than one variant were classified ADPKD-
PKD1/2T/NT based on the main variant.
To validate our method, LR-PCR re-sequencing was
performed on DNA from 18 ADPKD-PKD1 and 3 ADPKD-
PKD2 patients who had previously undergone genetic diagnosis
by Sanger sequencing. All the 21 potentially causative variants
known to be present in PKD1 (9 missense, 4 non-sense, 4 splicing
and 4 frameshift), as well as the three in PKD2 (2 frameshift and
1 missense), were correctly detected.
In order to confirm the accuracy of the method, we tested 36
additional patients with a clinical diagnosis of ADPKD, who had
already undergone kidney transplantation. In 28 individuals we
identified possible pathogenic variants (P or LP) in PKD1, 25 of
which were T and three NT. In three cases, protein truncating
variants in PKD2 were detected. Three patients showed a variant
of uncertain significance in PKD1. The low prevalence of PKD2
mutations (9.7%) compared to PKD1 (90.3%) in this cohort was
consistent with the disease severity in these patients.
We then applied the method to a group of 155 newly recruited
patients (discovery cohort). Among these cases, composed of
patients with varying degrees of disease severity, 72 patients
resulted positive for potentially causative variants in the PKD1
gene, 55 T and 17 NT, whereas 14 patients showed genetic defects
in PKD2 gene. In 21 cases, we identified a variant classified as
VUS, 18 in PKD1 and three in PKD2. In this discovery cohort, the
prevalence of PKD2mutations (16.3%) is higher when compared
to the confirmation cohort.
Overall, in confirmation and discovery cohorts, we detected
causative variants in 117 out of 191 patients, obtaining a
diagnostic rate of 61.3%; 85.5% of positives showed variants in
PKD1 gene, whereas 14.5% showed variants in PKD2. Diagnostic
rates are heterogeneous among different studies and can vary
in relation to the criteria for variant classification and the
proportion of typical/familial cases. A diagnostic rate of 80%
was reported in the only large Italian cohort of ADPKD
patients, including “highly likely” and “likely” pathogenic
variants (Carrera et al., 2016), but studies in other European
populations report lower diagnostic rates (Hoefele et al., 2011;
Obeidova et al., 2014).
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TABLE 3 | Types of 158 distinct possible pathogenic variants detected in PKD1
and PKD2 genes.
PKD1 variants PKD2 variants
N %A N %A N %A
All variants 158 100.0 139 88.0 19 12.0
N %B N %C
Novel 80 50.6 73 52.5 7 36.8
Known 78 49.4 66 47.5 12 63.2
De novo 7 4.4 6 4.3 1 5.3
Truncating 100 63.3 85 61.2 15 78.9
Non-truncating 58 36.7 54 38.8 4 21.1
Pathogenic 95 60.1 82 59.0 13 68.4
Likely pathogenic 25 15.8 21 15.1 4 21.1
VUS 30 19.0 28 20.1 2 10.5
Hypomorphic 8 5.1 8 5.8 0 0.0
Missense 54 34.2 50 36.0 4 21.1
Non-sense 46 29.1 41 29.5 5 26.3
Frameshift/indel 36 22.8 32 23.0 4 21.1
Splicing 10 6.3 6 4.3 4 21.1
Large rearrangements 8 5.1 6 4.3 2 10.5
In-frame indel 4 2.5 4 2.9 0 0.0
A% among all variants; B% among PKD1 variants; C% among PKD2 variants. Pathogenic,
Likely pathogenic and VUS are classified following American College of Medical Genetics
and Genomics standard.
Accuracy of the Method and Mutation
Spectrum
Since we re-sequenced all the possible pathogenic variants by
Sanger method, we have been able to calculate sensitivity,
specificity and accuracy of NGS, using the Sanger as gold
standard. Our NGS on LR-PCR for PKD1 and PKD2 genes
provided 100% sensitivity, 63% specificity and 92% accuracy.
Although we cannot rule out that some variants have not been
called by NGS, we have not recorded false negative. On the
other hand, detection of false positive variants was not so rare
(22/221, 10%) and usually involved GC reach regions and/or
homopolymers. However, the frequencies of the two called alleles
in these cases was usually unbalanced (Supplementary Table 2).
Two cases of allele-drop out of the wild-type allele were
detected, using LR-PCR amplification of exons 13–21 of PKD1.
In both cases, replacing the LR-PCR primers with those
previously described by Rossetti et al. (2012) for exons 15–21,
the heterozygous state of the mutations was called correctly. For
this reason, we decided to implement our analysis with this last
LR-PCR, to avoid possible pitfalls (Supplementary Table 1).
Types and numbers of the variants classified in the P, LP,
VUS, and H categories are listed in Table 3. Among the 158
different genetic alterations detected in our study, 80 (50.6%)
had not been previously described, 73 of which were found in
PKD1 and 7 in PKD2. Missense and non-sense were the most
frequent variants in both genes, followed by frameshift in PKD1
and by splicing and frameshift in PKD2. Six variants in PKD1
occurred de-novo, three of which were not previously described:
c.3236del p.(Asp1079Alafs∗25), c.8860G>T p.(Glu2954∗), and
c.9201+1G>A. One de-novo and novel variant was also detected
in PKD2: c.992G>A p.(Cys331Tyr).
All the 158 variants detected in PKD1 and PKD2 genes
that we classified as P, LP, VUS, and H are listed in
Supplementary Table 3, whereas the variants classified as LB
and B are not reported. The mutations were spread over almost
all exons, without hot spot regions. Seventeen mutations were
detected in two or more families not known to be related.
Ten index patients showed large rearrangements (6 in PKD1
and 4 in PKD2), four of which were not previously described.
These rearrangements could be detected by MLPA only, whereas
our NGS analysis was unable to reveal them with enough
accuracy. Among PKD1 deletions, we detected one single whole
gene deletion, a deletion of exon 40, and four intragenic multiple
exon deletions. In PKD2, a deletion of the whole gene was
detected in two patients, whereas the deletion of exons 8 and 9
was shown in other two cases.
The molecular visualization of uncertain and hypomorphic
variants performed by PyMol revealed alteration in only two
of them. After searching for hydrogen bonds within 5 residues
around the variants, we detected a bond loss for aminoacid
changes p.(Ala3958Pro) (previously undescribed and classified
as LB according to ACMG) and p.(Arg3277Cys) (previously
reported as H by Rossetti et al., 2009, but classified as LB by
ACMG) in Polycystin-1, as shown in Supplementary Figure 1.
These results suggest a possible pathogenic role for these variants.
Based on this prediction and thanks to segregation analysis we
re-classified these two variants as VUS and H, respectively.
Genotype-Phenotype Analyses
The relationship between affected genes and type of
mutation with main clinical features is presented in
Supplementary Table 4. A significant association was
detected with PKD1 truncating, PKD1 non-truncating and
PKD2 mutations vs. kidney transplantation (p = 0.0006),
antihypertensive treatment before 35 years (p = 0.0008),
urological events before 35 years (p= 0.02).
A significantly different mean age distribution of disease
onset (p = 0.0004), diagnosis (p = 0.0008) and ESRD (p =
0.04) was found among the cases with mutations in PKD1
and PKD2. Similar results were obtained by comparing the
patients with PKD1 truncated mutations, PKD1 non-truncated
and PKD2 mutations. ADPKD-PKD1T patients had an onset
of the disease, respectively >10 years and >19 years earlier
than ADPKD-PKD1NT and ADPKD-PKD2, as well as a 7 and
16 years earlier diagnosis, respectively. Moreover, ADPKD-
PKD1T patients experienced ESRD 9 and >13 years earlier
than ADPKD-PKD1NT and ADPKD-PKD2, respectively. These
genotype-phenotype correlations are in line with previously
published cohorts (Cornec-Le Gall et al., 2013; Hwang et al.,
2016).
We found that 23.3% of our patients were without an apparent
family history of polycystic kidney disease. Mutations in PKD1 or
PKD2were detected in 31 (68.9%) and five (16.1%) of these cases,
respectively (Table 4). We demonstrated that the mutation arose
de-novo in three patients, one case showed a somatic mosaicism,
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and five patients were carriers of two variants, partially explaining
the absence of family history for the disease. The remaining
14 patients without family history, resulted negative for PKD1
or PKD2 mutations. Among them, after clinical revision, 11
were submitted to additional cystogenes re-sequencing and one
of them resulted mutated in both allele of PKHD1, whereas
three were PKHD1 heterozygous carriers. We did not observe
significant clinical differences between patients with positive and
negative family history.
Probands With More Than One Variant
Although ADPKD is typically a late-onset disease, some patients
show an early and severe phenotype: ADPKDVEO (diagnosed
in utero or before 18 months) and ADPKDEO (diagnosed
before 15 years). Mutations in multiple PKD genes or biallelic
PKD mutations can often explain these phenotypes (Bergmann
et al., 2011; Audrézet et al., 2016), proving that additional
PKD alleles in trans and/or de novo exert an aggravating
effect and contribute to early and severe disease expression in
polycystic kidney disease. In our series, 30 index patients (18.4%)
TABLE 4 | Patients without family history of ADPKD.
N %
Cases without family history of ADPKD 45 23.3
Cases with PKD1/PKD2 variants 31 68.9
PKD1T 16 51.6
PKD1NT 10 32.3
PKD2 5 16.1
Cases with more than one variant 5 16.1
Cases with de-novo variants 3 9.7
Mosaicism 1 3.2
PKD1/PKD2 negative 14 31.1
Tested for other cystogenes 11 78.6
Cases with variants in other genes (PKHD1) 4 28.6
Family data was available for 193 index cases.
had either a prenatal identification of renal cysts or clinical
symptoms that allowed a diagnosis earlier than 15 years of
age (Table 1).
Segregation analysis, when performed in patients who
were found to carry more than one possible pathogenic
variant, demonstrated the presence of compound heterozigosity
in 6 and of a de novo variant in two (Table 5). Among
patients with two variants, there were 4 ADPKDVEO and
3 ADPKDEO. Patients who carried two variants in cis are
not reported.
Based on familial segregation or pathogenicity information,
these variants were classified as main and additional. In patients
with an early onset of disease, whenever the additional variant
was detected in trans, we re-classified it as hypomorphic, as it
likely contributed to worsening the phenotype. In six families,
we were able to diagnose a possible biallelic disease, resulting
from the presence of two variants in trans (either in the same or
different genes).
In four families, one variant was transmitted from a typically
affected parent to a child with early onset disease or to an
affected pregnancy, and a second hypomorphic variant was
transmitted by an unaffected parent. (1) The p.(Ser2000Cys)
(absent in GnomAD but with benign computational predictions)
was identified in a child with disease onset at 3 years, in trans
with a truncating mutation. (2) The p.(Pro2674Ser) variant
is frequent, but it was identified in a child with early onset
disease, in trans with a main variant, p.(Ala3958Pro), which was
present in her typically affected mother. (3) In family 18206,
two consecutive pregnancies were interrupted after sonographic
detection of renal cysts. The father had a diagnosis of ADPKD
and carried a frameshift mutation; molecular analysis of fetal
DNA identified a second variant transmitted by a healthymother,
p.(Ile3167Phe), which was initially defined as possibly pathogenic
(Rossetti et al., 2002), but is relatively frequent in the general
population; we propose that it may represent a hypomorphic
allele. (4) In family 18477, a pregnancy was interrupted after
sonographic detection of renal cysts and PKD1 analysis revealed
two variants: p.(Arg459Pro), transmitted by the affected father,
TABLE 5 | Probands with more than one variant.
ID Main variant Additional variant Phase Affected relative Age at diagnosis
15686 PKD1: c.2098-2_2109del PKD1: p.R3247C uk None 20
16051 PKD1: p.E3872* PKD1: p.S2757C uk Daughter 42
16533 PKD1: p.D1079Afs*25 PKD1: p.T2250M dn None 3 (EO)
16813 PKD1: p.Q493* PKD1: p. R944C uk None uk
17016 PKD1: p.Y1599* PKD1: p.S2000C trans Mother 3 (EO)
17045 PKD1: p.R3277C PKD1: p.R3277C trans None 22
17469 PKD1: p.A3958P PKD1: p.P2674S trans Mother 10 (EO)
17474 PKD1: p.N2167D PKD1: p.A561V dn None Pn (VEO)
18206 PKD1: p.L1479Wfs*55 PKD1: p.I3167F trans Father Pn (VEO)
18287 PKD2: p.C331Y PKD1: p.S123T; trans Mother Pn (VEO)
PKD2: p.R872G
18477 PKD1: p.R459P PKD1: p.G1185D trans Father Pn (VEO)
The cases who presented the variants in cis are not reported. VEO, Very Early Onset; EO, Early Onset; uk: unknown; dn, de novo; Pn, Prenatal. *stop codon (Ter).
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and p.(Gly1185Asp), present in the mother, who had no renal
cysts; a healthy child was born from a second pregnancy and
he was found to carry the p.(Gly1185Asp) only. Although the
p.(Arg459Pro) is extremely rare (never reported before, absent
in GnomAD), it is likely benign according to ACMG guidelines;
we cannot exclude that it might be in cis with an unidentified
pathogenic variant.
In family 17045, a homozygous missense variant in PKD1 was
detected. The proband showed an equivocal disease presentation
and negative family history, but the first clinical hypothesis, at 22
years of age, was ARPKD. As PKHD1 screening resulted negative,
ADPKD genes were studied and homozygosity for the known
hypomorphic variant p.(Arg3277Cys) was identified (Rossetti
et al., 2009). Interestingly, PyMol analysis, as well additional
bioinformatics tools, predicted a possible pathogenicity for
this variant. MLPA did not identify any deletion and no
consanguinity was recorded.
Two patients showed ADPKDEO and ADPKDVEO,
respectively, and both were carriers of a de novo P/LP PKD1
variant and a second heterozygous variant. Patient 16533 was a
15 years old boy who showed an episode of macroematuria at
the age of three; abdominal ultrasound showed multiple cysts in
both kidneys and the number of cysts and total kidney volume
progressed over time. Family history was negative and he was
found to carry a de novo pathogenic (frameshift) mutation
and the p.(Thr2250Met) variant, inherited from his healthy
father. The latter variant is relatively frequent in the general
population and was already reported as a possible hypomorphic
allele in previous studies (Irazabal et al., 2011). In family 17474,
renal cysts were detected prenatally and confirmed after birth,
parents are healthy (no cysts detected at renal ultrasound)
and non-consanguineous. PKD1 sequencing identified a likely
pathogenic variant, p.(Asn2167Asp), absent in parents, and
a second maternally inherited variant, p.(Ala561Val). This is
extremely rare (never reported before, absent in GnomAD), but
with benign computational predictions, and it was classified as
hypomorphic. We cannot formally test if variants in these two
patients are in trans, but we presume they contributed to the
severe clinical expression.
In family 18287 we detected a possible bilineal inheritance,
with variants in both PKD1 and PKD2 (Figure 1). Two
pregnancies were interrupted due to a prenatal finding of
polycystic kidney disease at ultrasound examination at 20
and 13 gestational weeks, respectively. The mother was 33
year old; she had multicystic bilateral disease without affected
family members, and showed a de novo missense variant
p.(Cys331Thr) in PKD2. The father was a healthy 44 years
old man with no signs of kidney cystic disease at ultrasound,
and showed a variant in PKD1, p.(Ser123Thr), and a second
variant in PKD2, p.(Arg872Gly). Both fetuses inherited the
maternal PKD2 missense variant, in addition to the paternal
p.(Ser872Gly) variant in PKD1, while only one fetus inherited the
p.(Arg872Gly) PKD2 variant. The analysis of PKHD1 performed
on the first fetus showed no mutations. We suggest that: 1) the
PKD2 p.(Cys331Thr) variant is pathogenic, since it is de-novo in
a patient with a renal cystic disease and is transmitted to both
fetuses; 2) the p.(Ser123Thr) variant in PKD1 is hypomorphic,
FIGURE 1 | Pedigree of Family 18287 with bilineal inheritance of PKD1/PKD2
variants. Variants segregating with disease are shown in bolt.
since it does not cause renal disease in the father (age 44
years), but worsens the renal phenotype when co-inherited with
a PKD2 mutation; 3) the missense variant p.(Arg872Gly) in
PKD2, already described as disease-causing in HGMD database
(Neumann et al., 2013), is likely benign, since it is present
in a healthy man and does not segregate with disease in
the fetuses.
Bilineal inheritance of PKD1 and PKD2 variants is an
extremely rare finding and, as expected, disease associated with
the presence of two distinct mutations appeared to be more
severe than the disease associated with either mutation alone (Pei
et al., 2001; Elisakova et al., 2018).
Detection of Mosaicism
The high sensitivity of NGS technology allowed us to detect two
cases of mosaicism.
Case 1. A 53-year-old male proband was first evaluated at the
age of 34, when he had an episode of hematuria. Abdominal
US documented bilateral multiple renal cysts without hepatic
involvement. He started treatment for arterial hypertension
at the age of 40 years and he underwent to hemodialysis at
48 years old. He received a kidney transplant 2 years later.
The molecular analysis showed the heterozygosis for c.2986-
2_2987del splicing mutation in PKD1: this four-nucleotide
deletion between intron12 and exon13 was predicted to alter
an acceptor site, affecting splicing. The proband’s mother was
also diagnosed with ADPKD at the age of 67 years, when
she performed an ultrasound for abdominal pain, although
she showed a milder phenotype (renal and hepatic cysts
but normal renal function at 69 years) and no other family
members were reported to be affected. The c.2986-2_2987del
mutation was not detected by targeted Sanger sequencing
in the mother. NGS of whole PKD1 was later performed
on maternal DNA and the mutation c.2986-2_2987del was
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FIGURE 2 | Two cases of mosaicism. (A) Family 16321, where the affected mother showed 6.9% of mutated PKD1 in peripheral blood. (B) Family 17747, where the
proband showed 15.9% of mutated PKD1. The reads are visualized by Integrative Genome Viewer (IGV) software.
detected in 156 among 2,193 reads, revealing a 6.9% of
mosaicism in peripheral blood. Of note, the mutation was not
sufficient for the germinal variant calling (threshold defined
by our bioinformatics pipeline was 10%), but it was readable
by IGV software (Figure 2A).
Case 2. A 63-year-old female patient, diagnosed at 46
years and without familiarity for the disease, showed no
heterozygous mutations or rearrangements in PKD1 and
PKD2 genes. However, a 2bp deletion (c.9965_9966del)
in exon 30 of PKD1 gene was detected in 40 among 252
(15.9%) reads. Sanger sequencing by using two different
gene-specific LR-PCR primers pair and two different
sequencing primers pair confirmed the presence of the
mosaicism (Figure 2B).
Patients Without PKD1 and/or PKD2
Mutations
In 74 index patients, neither pathogenic/likely pathogenic
variants nor rearrangements were identified in both PKD1 and
PKD2, although 24 of them showed a VUS. Family data were
recorded for 42 cases, and 28 had a family history of polycystic
disease. Among families, disease progression was typical in at
least eight, while it was very mild and/or atypical (based on
imaging studies) in the remaining 14 families. The median age
of disease onset was 30 years; six patients had reached ESRD
and three underwent renal transplantation. After re-evaluation
of the clinical phenotype, 28 of these patients were tested for
an additional NGS-panel that included the recently described
genes associated with ADPKD and ADPLD, PKHD1 and some
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TABLE 6 | Molecular defects in additional cystogenes detected in 25 PKD1/PKD2-negative cases.
ID Age at diagnosis Gene Exon Protein cDNA ACMG classification
16542 42 PKHD1 58 p.H3124Y c.9370 C>T VUS
PMM2 2 p.G42R c.124 G>A LP
16672 41 PKHD1 66 p.R3913C c.11737C>T VUS
17254 15 PKHD1 5 p.R124* c.370C>T P
17316 17 PKHD1 3 p.T36M c.107C>T LP
PKHD1 46 p.C2422G c.7264T>G LP
17654 61 ALG8 4 p. L149R c.446T>G VUS
18607 59 PRKCSH 15 p.Y423* c.1269C>G LP
ACMG, American College of Medical Genetics and Genomics standard. *stop codon (Ter).
FIGURE 3 | Kidney and liver images of two patients. (A) MRI of a 31-year-old woman with compound heterozygous mutations in PKHD1, who received a diagnosis of
polycystic kidneys at 17. (B) MRI of a 45-year-old woman, who carried two heterozygous variants in PKHD1, p.(His3124Thr), and PMM2, p.(Gly42Arg).
additional cystogenes. Six patients showed variants in one or
more of these genes, as reported in Table 6.
Patient 17316 carried compound heterozygous mutations
in PKHD1, hence a diagnosis of ARPKD could be posed.
She was a 31 years old woman who received a diagnosis of
polycystic kidneys at 17. At 30, after her first pregnancy, she
had proteinuria, multiple cysts in both kidneys and a mild
reduction of GFR. No family members were reported to be
affected by polycystic kidney and ADPKD gene testing resulted
negative. An abdominal computed tomography scan showed, in
addition to the known renal cysts, segmental dilatation of the
intrahepatic bile ducts compatible with Caroli disease. PKHD1
analysis identified two mutations in compound heterozygosity,
p.(Thr36Met) and p.(Cys2422Gly). MRI is shown in Figure 3A.
Three additional patients showed heterozygous
variants in PKHD1 (MLPA excluded large intragenic
deletions/duplications). Monoallelic mutations in PKHD1 have
been described to cause multiple liver cysts and/or increased
kidney echogenicity in up to 10% of carriers, but were not
associated with an increased risk of renal cysts (Gunay-Aygun
et al., 2011). Patient 17254 carried a definitely pathogenic variant,
p.(Arg124∗): she was a 50 year old woman, renal cysts were
identified when she was 15, but the disease was non progressive,
she had no hepatic cysts and no family history. The PKHD1
mutation likely represents a spurious finding. Also patient 16672,
a 42 year old man, found out to have renal cysts at the age of 40,
together with multiple hepatic cysts; he carried a heterozygous
variant of unknown significance, p.(Arg3913Cys).
Finally, patient 16542 was diagnosed with PKD at the age
of 30 years, after the onset of arterial hypertension (MRI is
shown in Figure 3B); she had normal renal function at last
evaluation (45 years). Her father died at the age of 79, he had
type 2 diabetes requiring insulin treatment, renal and hepatic
cysts detected at ultrasonography and normal renal function. The
patient carried a heterozygous variant of unknown significance in
PKHD1, p.(His3124Tyr), defined as likely pathogenic in ClinVar,
and a missense variant p.(Gly42Arg) in PMM2, classified as
likely pathogenic. Recessive mutations in PMM2 were reported
as associated to hyperinsulinemic hypoglycemia (HI) and PKD
(Cabezas et al., 2017). The study of larger cohorts of patients
will be able to define if the combination of variants in distinct
recessive genes can be relevant for cysts progression.
Patient 17654 was diagnosed with polycystic kidney disease
at the age of 61 on routine abdominal US examination. He has
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renal and hepatic cysts but normal renal function. His 89-year-
old mother has renal and liver cysts, and a nephrocalcinosis. An
uncle, who died at the age of 85, had kidney cysts and mild renal
insufficiency. Molecular analysis showed a variant of uncertain
significance in ALG8, p.(Leu149Arg), which is extremely rare
in the general population and has a pathogenic computational
verdict with no benign predictions. ALG8 was recently described
as a very rare cause of ADPLD, but at least one patient had
renal cysts at a young age (Besse et al., 2017). In our family, the
p.Leu149Arg variant was present in the proband’s mildly affected
mother. ALG8 may be the cause of polycystic disease in this
family, although a functional assay would be needed to prove the
involvement of this variant beyond doubt.
Patient 18607 was diagnosed with polycystic disease at the age
of 49, with cysts mainly affecting the liver. Family history was
not known, but she carried a non-sense mutation p.(Tyr423∗) in
PRKCSH, a gene associated to polycystic liver disease-1 (PCLD1)
with or without kidney cysts (Fedeles et al., 2011). The same
mutation, p.(Tyr423∗), was already reported in a family with
autosomal dominant polycystic liver disease (Li et al., 2003).
DISCUSSION
Genetic testing in the clinical management of ADPKD is
not widespread for several reasons. First, analysis of PKD1 is
challenging due to its segmentally duplicated region. Second,
the genetic heterogeneity and the extreme allelic heterogeneity
(>1.500 different pathogenic variants described for PKD1)
require analysis of the coding regions of all candidate genes,
and Sanger-based single gene approaches are costly and
cumbersome. Third, the presence of many non-truncating
alleles and potentially hypomorphic low-penetrance variants
pose a further challenge for clinical interpretation. However,
genetic testing is increasingly required for diagnosis, prognosis
and treatment decision. Furthermore, molecular testing can
provide genetic stratification for clinical trials and may guide
clinical management.
In the present study, we validated a targeted-NGS method,
which was adjusted in a diagnostic setting, and we applied it
to analyze a cohort of 212 ADPKD patients. Our protocol is
based on high-throughput simultaneous sequencing of PKD1 and
PKD2 after LR-PCR of coding regions, followed by a masked
reference genome alignment. Samples without PKD1/PKD2
mutations were submitted to MLPA and, when negative, tested
by targeted-NGS for mutations in newly described ADPKD and
ADPLD genes, ARPKD and additional cystogenes.
Our protocol overcomes the technical issues of PKD1 analysis,
provides a reliable and less expensive molecular test for both
genes, and resulted highly accurate. The use of previously
validated primers for gene-specific enrichment, the introduction
of an additional LR-PCR in order to minimize the risk of allele-
drop out, and a specific alignment pipeline for avoiding miss-
alignment with pseudogenes, make our genetic test specific and
robust. Nevertheless, we cannot exclude that few variants were
missed due to non-amplification of one allele.
Overall, we detected a pathogenic/likely pathogenic variant
in 63.9% (122 among 191) of our index patients, 100 (82.0%)
of which showed a genetic defect in PKD1, 17 (14%) in
PKD2 and 5 (4%) in other cystogenes. In addition, 26
probands (13.6%) presented variants in these genes classified as
uncertain significance.
Several studies have demonstrated that patients with PKD1
mutations predicted to truncate the protein have a more severe
phenotype than patients with non-truncating mutations and
patients with PKD2 mutations. In addition, hypomorphic alleles
are reported in patients with milder kidney disease and in
normal individuals, but can cause a severe early onset disease
if they are present in trans with a pathogenic variant. Hence,
we also included gene and type of detected variant in the
nosology of our patient cohort (Cornec-Le Gall et al., 2013; Heyer
et al., 2016; Hwang et al., 2016). In our study, we detected a
higher prevalence of ADPKD-PKD1T cases in the confirmation
cohort (89.3%) in comparison to that in the diagnostic cohort
(76.4%), according to the different clinical phenotype of patients
in the two groups. Moreover, our overall results confirm that
patients with PKD1 mutations predicted to truncate the protein
experienced ESRD 9 years earlier than patients with PKD1 non-
truncating mutations and >13 years earlier than patients with
PKD2mutations. In addition, our ADPKD-PKD1T cases showed
an onset of the disease significantly earlier thanADPKD-PKD1NT
and ADPK-PKD2 (>10 and >19 years, respectively), as well as a
significant earlier diagnosis (7 and 15 years, respectively). These
data emphasize the need to combine clinical information with
gene and allele data to achieve useful prognostic predictions. The
incomplete penetrance of some PKD alleles and a dosage effect
must be taken into account.
Among 158 distinct variants here detected, 80 (50.6%) were
previously unreported, confirming the high allelic heterogeneity
of these genes, which harbor many clinically significant
private variants. Differentiating pathogenic from neutral changes
remains a big challenge, since 36.7% of the variants here
detected were non-truncating, 19% were classified as variants of
uncertain significant and 5.1% were likely hypomorphic alleles.
Our additional bioinformatics analysis using PyMOL helped us
to better define the potential pathogenicity of some VUS and
H variants. However, variant interpretation remains the major
bottleneck in NGS analysis and data sharing is essential, in
order to collect more families where segregation analysis can
be performed. It is notable that, when strictly following ACMG
guidelines, the only non-truncating PKD1/PKD2 variants that
reach the status of “likely pathogenic” are either described in
previous studies or segregate in affected family members. We
did our best to organize and perform segregation analysis in as
many families as possible. Functional studies to evaluate PKD1
and PKD2 variants would be extremely useful but, unfortunately,
are currently unavailable.
A further key point is the distinction between neutral and
hypomorphic alleles and the degree of their penetrance. This is
relevant in order to select potential kidney donors and to assess
the risk of biallelic disease when a hypomorphic variant is present
in trans with a fully inactivating PKD1 allele. Indeed, some
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ADPKD and ARPKD patients can clinically overlap with early
manifestation in ADPKD and late onset in ARPKD.Mutations in
PKD1 and PKD2 can also be inherited in a recessive way with at
least one PKD1 or PKD2 hypomorphic allele (Bergmann, 2017).
In our study, eleven patients (9.4% of mutated) showed more
than one variant. Segregation analysis indicated biallelic disease
in five patients, digenic in one, de-novo variant with unknown
phase in two, and segregation analysis was not possible in three
patients. Seven patients with very early onset disease and 23
patients with early onset were present in our series, and 23.3%
(7 out 30) of them exhibited two variants, typically compound
heterozygosis of a pathogenic and a hypomorphic allele.
We found a further clinical phenocopy of ARPKD, due to
homozygosity of the PKD1 hypomorphic allele p.(Arg3277Cys),
in a patient with negative family history (ID 17045). This variant
is reported as an incompletely penetrant mutant allele that
resulted in occasional cyst development in heterozygotes and
more severe PKD in homozygosity (Rossetti et al., 2009). Our
data confirmed that the dosage/threshold of functional PKD1
protein might be critical for cyst initiation. Of note, the in silico
analysis by PyMol indicated that this variant results in a bond loss
in Polycystin-1.
A case of ADPKDVEO caused by digenic disease with PKD1
and PKD2 genetic defects was also detected. Digenic disease
involving PKD1 and PKD2 genes are rarely described, and it
usually results in more severe clinical phenotype than in cases
with mono-allelic variants, but not in VEO (Pei et al., 2001;
Gainullin et al., 2015). The co-inheritance of a pathogenic
allele in PKD2 (from the affected mother) and a hypomorphic
variant in PKD1 from the unaffected father, likely caused a
severe phenotype in this family. To our knowledge, this is the
first report of bilineal inheritance causing prenatal onset of
polycystic kidneys.
We found one patient with biallelic mutations in PKHD1
among probands negative for PKD1/PKD2 mutations,
confirming the significant overlap between ARPKD andADPKD.
ARPKD is usually a severe early onset disease, but there is wide
variability in severity even among patients carrying the same
PKHD1 mutations, emphasizing the importance of modifying
genes and potential environmental factors (Gunay-Aygun et al.,
2010). In a sporadic patient with adult-onset polycystic kidneys,
the diagnosis of ARPKD should be considered. Such cases
highlight the importance of the molecular diagnosis: knowing
the genetic cause of the disease allows an adequate clinical
management and a proper genetic counseling.
NGS has the advantage of deep sequencing and allows the
detection of mosaicism, undetectable by Sanger sequencing.
Somatic mutations acquired in the early stage of embryonic
postzygotic development might cause mosaicism in the parent
who later transmits the mutation to the offspring through germ
cell. One case of mosaicism arising from this mechanism was
detected in our study: the heterozygous PKD1mutation detected
in the affected proband was inherited from the less severely
affected mother, who showed only 6.8% of mutated reads in
her peripheral blood. An additional case of somatic mosaicism
has been detected, with 15.9% of mutated reads in PKD1
gene. No offspring was available to test the heritability of this
genetic defect. The incidence of mosaicism events in the human
body is underestimated, but a mosaicism should be considered
in patients with mild disease and healthy parents or with
unclear pattern of transmission. In addition, apparently de-novo
mutations might indeed be the consequence of somatic/germline
mosaicism in an unaffected parent. In current diagnostic
protocols, targeted deep sequencing of the mutation detected in
the index case should be performed in the unaffected parents.
Our NGS protocol represented a useful diagnostic tool for the
detection of somatic mosaicism.
In conclusion, accurate and cost-effective diagnostic genetic
tests are needed in order to drive clinical management of
polycystic kidney disease. NGS technology represents a powerful
approach for a better understanding of this disorder, overcoming
at least part of the technical difficulties of PKD2/PKD1molecular
analysis. However, interpretation of results remains challenging
and requires interdisciplinary efforts as well as broad genetic and
phenotypic data sharing.
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